Isogenica Expands Discovery Capacity

Isogenica Ltd. has opened a new automation facility at its current location, Chesterford Research Park in Cambridge. The new facility will house the high throughput CIS display platform for the discovery of biological therapeutics, diagnostics and reagents using Tecan liquid handling robots and screening equipment, adding capacity for the selection of next generation molecules for biopharmaceutical projects with as many as two hundred selections per week.

Kevin Matthews, chief executive officer, Isogenica, said, “We are delighted to have been able to expand our capabilities with the opening of this new facility, a primary benefit of which will be our ability to further the industrialization of our CIS display technology. Our significant investment in this new facility is to accommodate recent increases in activity in our peptide/protein selection platform and to fulfill future demand from both industry and academia.”

In March Isogenica entered a service agreement with Johnson & Johnson Pharmaceutical R&D for discovery work with the Centyrin scaffold. Also, in June the company partnered with Biolauncher and Cresset Biomolecular Discovery to develop an end-to-end small molecule discovery platform by integrating their expertise in peptide library design, evolutionary screening, next generation sequencing, structural analytics, and molecular field-based computational chemistry to identify active compounds against high-value therapeutic targets.